X 4 Pharmaceuticals Inc (XFOR)

Apr 04, 2025

Now Pharma Inc looks for cure as Trump delivers dose of anxiety - The Economic Times

Apr 04, 2025

Apr 04, 2025

Layoff Tracker: Relay Will Cut 70 Employees, Affecting Research Budget by 75% - BioSpace

Apr 04, 2025

Apr 04, 2025

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Apr 04, 2025

Apr 04, 2025

Fierce Biotech Layoff Tracker 2025: Relay sheds staff again; Sail lays off employees - Fierce Biotech

Apr 04, 2025

Apr 03, 2025

Crescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class Oncology Therapeutics - Quantisnow

Apr 03, 2025

Apr 01, 2025

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Apr 01, 2025

Apr 01, 2025

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Apr 01, 2025

Apr 01, 2025

Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti™ for the Treatments of Acute Bipolar I Disorder and Schizophrenia - BioSpace

Apr 01, 2025

Mar 31, 2025

Ionis to present at upcoming investor conferences - Quantisnow

Mar 31, 2025

Mar 31, 2025

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q4 2024 Earnings Call Transcript - MSN

Mar 31, 2025

Mar 29, 2025

Research Analysts Issue Forecasts for XFOR FY2028 Earnings - Defense World

Mar 29, 2025

Mar 28, 2025

X4 Pharmaceuticals (NASDAQ:XFOR) Receives “Buy” Rating from HC Wainwright - Defense World

Mar 28, 2025

Mar 27, 2025

XFOR: Full Enrollment of Phase 3 4WARD Trial Expected in 2H25… - Yahoo Finance

Mar 27, 2025

Mar 27, 2025

Breaking Down X4 Pharmaceuticals: 4 Analysts Share Their Views - Benzinga

Mar 27, 2025

Mar 27, 2025

H.C. Wainwright maintains Buy on X4 Pharma, target at $1.50 - Investing.com

Mar 27, 2025

Mar 26, 2025

X4 Pharmaceuticals Inc (XFOR) Q4 2024 Earnings Call Highlights: - GuruFocus

Mar 26, 2025

Mar 26, 2025

X4 Pharmaceuticals Inc (XFOR) Q4 2024 Earnings Call Highlights: Strategic Restructuring and ... - Yahoo Finance

Mar 26, 2025

Mar 26, 2025

X4 Pharmaceuticals Inc (XFOR) Q4 2024 Earnings Call Highlights: Strategic Restructuring and ... By GuruFocus - Investing.com Canada

Mar 26, 2025

Mar 25, 2025

Stifel cuts X4 Pharmaceuticals target to $3, maintains buy rating - Investing.com

Mar 25, 2025

Mar 25, 2025

Brookline maintains Buy on X4 Pharma, keeps $4 price target By Investing.com - Investing.com UK

Mar 25, 2025

Mar 25, 2025

X4 Pharmaceuticals: Q4 Earnings Snapshot - The Washington Post

Mar 25, 2025

Mar 25, 2025

Earnings call transcript: X4 Pharmaceuticals Q4 2024 misses EPS forecast - Investing.com

Mar 25, 2025

Mar 25, 2025

X4 Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 25, 2025

Mar 25, 2025

X4 Pharmaceuticals Inc (XFOR) Q4 2024 Earnings: Revenue Surpasses Estimates at $1.4M, EPS Misses at -$0.20 - GuruFocus

Mar 25, 2025

Mar 25, 2025

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - The Manila Times

Mar 25, 2025

Mar 25, 2025

X4 Pharmaceuticals Announces Activation of Phase 3 4WARD Trial for Chronic Neutropenia and 2024 Financial Results - Nasdaq

Mar 25, 2025

Mar 25, 2025

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is favoured by institutional owners who hold 70% of the company - Yahoo Finance

Mar 25, 2025

Mar 24, 2025

X4 Pharmaceuticals Inc (XFOR) Q4 2024 Earnings Report Preview: What To Look For - Yahoo Finance

Mar 24, 2025

Mar 24, 2025

X4 Pharmaceuticals Inc (XFOR) Q4 2024 Earnings Report Preview: W - GuruFocus

Mar 24, 2025

Mar 21, 2025

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Mar 21, 2025

Mar 21, 2025

X4 Pharmaceuticals Inc expected to post a loss of 17 cents a shareEarnings Preview - TradingView

Mar 21, 2025

Mar 21, 2025

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Mar 21, 2025

Mar 21, 2025

Prescription Drug Costs | Pros, Cons, Debate, Arguments, Economy, Laws, Government, & Regulation - Britannica

Mar 21, 2025

Mar 20, 2025

SEC Form 10-K filed by Sionna Therapeutics Inc. - Quantisnow

Mar 20, 2025

Mar 20, 2025

Form 10-K Sionna Therapeutics, For: Dec 31 - StreetInsider.com

Mar 20, 2025

Mar 19, 2025

This Pharmaceutical Company Completes 100 per cent Acquisition of Antibe Therapeutics for CAD 4.5 Million - Dalal Street Investment Journal

Mar 19, 2025

Mar 19, 2025

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Short Interest Update - Defense World

Mar 19, 2025

Mar 18, 2025

Alkaptonuria Therapeutics Market to Reach US$ 31.6 Million - GlobeNewswire

Mar 18, 2025

Mar 18, 2025

Breast Cancer Clinical Pipeline | 100+ Companies, Including - openPR

Mar 18, 2025